Biotech M&A is back. Ipsen set to fork out up to $1.3B for rare disease specialist Clementia
Merger Monday is back in full swing. Along with Roche buying Spark Therapeutics $ONCE, Parisian biotech Ipsen (Euronext: $IPN) is beefing up its rare …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
